The treatment of advanced melanoma has been dramatically improved by the anti–programmed cell death protein 1 (anti–PD-1) agents, two of which became available for this malignancy in 2014: nivolumab (Opdivo) and pembrolizumab (Keytruda). Here, PDCD1 is linked to melanoma.